全文获取类型
收费全文 | 5254篇 |
免费 | 308篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 192篇 |
妇产科学 | 126篇 |
基础医学 | 611篇 |
口腔科学 | 153篇 |
临床医学 | 388篇 |
内科学 | 1735篇 |
皮肤病学 | 66篇 |
神经病学 | 452篇 |
特种医学 | 97篇 |
外科学 | 604篇 |
综合类 | 16篇 |
一般理论 | 1篇 |
预防医学 | 218篇 |
眼科学 | 27篇 |
药学 | 388篇 |
中国医学 | 7篇 |
肿瘤学 | 483篇 |
出版年
2023年 | 29篇 |
2022年 | 46篇 |
2021年 | 136篇 |
2020年 | 58篇 |
2019年 | 125篇 |
2018年 | 130篇 |
2017年 | 102篇 |
2016年 | 111篇 |
2015年 | 106篇 |
2014年 | 168篇 |
2013年 | 236篇 |
2012年 | 295篇 |
2011年 | 284篇 |
2010年 | 163篇 |
2009年 | 155篇 |
2008年 | 235篇 |
2007年 | 304篇 |
2006年 | 290篇 |
2005年 | 297篇 |
2004年 | 234篇 |
2003年 | 215篇 |
2002年 | 218篇 |
2001年 | 167篇 |
2000年 | 169篇 |
1999年 | 154篇 |
1998年 | 46篇 |
1997年 | 47篇 |
1996年 | 41篇 |
1995年 | 43篇 |
1994年 | 37篇 |
1993年 | 30篇 |
1992年 | 99篇 |
1991年 | 61篇 |
1990年 | 77篇 |
1989年 | 63篇 |
1988年 | 58篇 |
1987年 | 66篇 |
1986年 | 50篇 |
1985年 | 53篇 |
1984年 | 44篇 |
1983年 | 53篇 |
1982年 | 20篇 |
1979年 | 26篇 |
1978年 | 20篇 |
1976年 | 17篇 |
1975年 | 25篇 |
1974年 | 28篇 |
1971年 | 16篇 |
1970年 | 20篇 |
1968年 | 16篇 |
排序方式: 共有5591条查询结果,搜索用时 31 毫秒
31.
Impaired H-2 expression in B16 melanoma variants 总被引:1,自引:0,他引:1
P Nanni M P Colombo C De Giovanni P L Lollini G Nicoletti G Parmiani G Prodi 《Journal of immunogenetics》1983,10(5):361-370
We studied the expression of H-2b alloantigens in three different B16 melanoma lines cultures in vitro. Cell lines were B16-F1 and two cell cultures (named B16-A and B16-B) newly derived from two different in vivo sublines of B16 melanoma. The assays used were in vivo tumour growth in allogeneic (BALB/c and B10.BR) as compared to syngeneic mice, in vitro cell-mediated cytotoxicity by anti-H-2b immune lymphocytes and absorption of anti-H-2b antisera activity. The B16-F1 line was able to efficiently kill allogeneic hosts, could not be lysed by anti-H-2b cytotoxic effectors and did not express any serologically detectable amount of H-2b alloantigens. The B16-A line was H-2 positive during the early in vitro passages, then, at the 8th-10th passages, it acquired the capacity to kill allogeneic hosts, lost the sensitivity to anti-H-2b cytotoxic effectors and the H-2Kb antigens became undetectable The expression of H-2Db was reduced, although at a lower degree. Similar data were obtained with B16-B cells, which after 10 in vitro passages grew and killed allogeneic hosts, showed a decreased sensitivity to cytotoxic anti-H-2b effectors and a very low expression of the K region antigens. The results indicate that H-2 expression is altered in B16 melanoma lines and this may influence the different metastatic capacity of such cells. 相似文献
32.
33.
34.
Carolina Scagnolari Francesca Bellomi Ombretta Turriziani Francesca Bagnato Valentina Tomassini Vito Lavolpe Marilena Ruggieri Fabrizio Bruschi Giuseppe Meucci Giordano Dicuonzo Guido Antonelli 《Journal of interferon & cytokine research》2002,22(2):207-213
The frequencies of anti-interferon-beta (IFN-beta) antibody development reported to date in patients treated with different IFN-beta preparations are not readily comparable mainly because of differences in underlying diseases and assay methods. Thus, the frequency of neutralizing antibody (NAb) and binding antibody (BAb) development was analyzed in a sample of sera derived from a homogeneous group of relapsing-remitting multiple sclerosis (RRMS) patients treated with different IFN-beta preparations. The frequency of developing NAb and BAb to IFN-beta varied according to the IFN-beta given. Specifically, the NAb seroconversion frequency was significantly higher in patients treated with Betaferon, Schering AG, Berlin, Germany (31.3%) than in patients treated with both preparations of recombinant IFN-beta 1a (Rebif, Serono, Geneva, Switzerland [7.4%] or Avonex, Biogen, Cambridge, MA [6.3%]). Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-beta preparations may also have different capability to induce BAb development and that BAb are produced during IFN-beta therapy at a significantly higher rate than NAb. Our main conclusion is that different human IFN-beta preparations may possess different immunogenicities, leading to varying frequency of development of antibody to IFN-beta in RRMS. 相似文献
35.
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia 总被引:2,自引:0,他引:2
36.
Haemophilus influenzae porin induces Toll-like receptor 2-mediated cytokine production in human monocytes and mouse macrophages 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Infection and immunity》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Galdiero M Galdiero M Finamore E Rossano F Gambuzza M Catania MR Teti G Midiri A Mancuso G 《Infection and immunity》2004,72(2):1204-1209
The production of proinflammatory cytokines is likely to play a major pathophysiological role in meningitis and other infections caused by Haemophilus influenzae type b (Hib). Previous studies have shown that Hib porin contributes to signaling of the inflammatory cascade. We examined here the role of Toll-like receptors (TLRs) and the TLR-associated adaptor protein MyD88 in Hib porin-induced production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6). Hib porin-induced TNF-alpha and IL-6 production was virtually eliminated in macrophages from TLR2- or MyD88-deficient mice. In contrast, macrophages from lipopolysaccharide (LPS)-hyporesponsive C3H/HeJ mice, which are defective in TLR4 function, responded normally to Hib porin. Moreover anti-TLR2 antibodies but not anti-TLR4 antibodies significantly reduced Hib porin-stimulated TNF-alpha and IL-6 release from the human monocytic cell line THP-1. These data indicate that the TLR2/MyD88 pathway plays an essential role in Hib porin-mediated cytokine production. These findings may be useful in the development of alternative therapies aimed at reducing excessive inflammatory responses during Hib infections. 相似文献
37.
38.
Paola Paglia Ivano Arioli Nicole Frahm Trinad Chakraborty Mario P. Colombo Carlos A. Guzmn 《European journal of immunology》1997,27(6):1570-1575
Listeria monocytogenes has been proposed as a carrier to elicit major histocompatibility complex class-I restricted immune responses able to protect against tumor challenge. In this study the properties of the attenuated L. monocytogenes Δmpl2 mutant has been evaluated in vivo against a highly aggressive mouse fibrosarcoma which expresses β-galactosidase (β-gal) as a tumor-associated antigen (TAA). Immunization with the vaccine prototypes resulted in both elicitation of specific antibodies and generation of cytotoxic lymphocytes (CTL). Oral vaccination protected 55–64% of the immunized animals from tumor take (p < 0.01) and strongly reduced the average size of the tumor in the other 34–45% (p < 0.01). Vaccinated mice developed a long-lasting response, which resulted in 100% protection from a subsequent tumor challenge. Substitution of the whole TAA by its CTL-defined immunodominant epitope resulted in 43% protection, suggesting a contribution of the humoral response to the observed antitumor effect. No statistically significant differences were observed in the antitumor response when mice were immunized with strains expressing the immunodominant TAA epitope in the context of carrier proteins which were either exported or restricted to the bacterial cytoplasm. This suggests that the topology of the recombinant antigen does not play a major role in the outcome of the protective response. 相似文献
39.
Clerici M Cogliati M Rizzardini G Colombo F Fossati S Rhodes J Bray D Piconi S 《Clinical immunology (Orlando, Fla.)》2000,97(3):211-220
The immunomodulatory properties of tucaresol (compound 589C80) were tested on in vitro antigen- and mitogen-stimulated proliferation and cytokine production by peripheral blood mononuclear cells (PBMC) of HIV-infected individuals and healthy controls (HC). Results showed that tucaresol: (1) increases influenza A virus-, gp 160 peptide-, and HLA alloantigen-stimulated proliferation as well as interleukin (IL)-2 and interferon gamma (IFN gamma) production by PBMC of HIV-infected individuals with higher CD4 counts (>500/microl) but had only a marginal immunomodulatory effect on PBMC of patients with lower CD4 counts (<500/microl); (2) did not modify IL-10 production; (3) augmented CD25 expression on mitogen-stimulated T cells of HC but not of HIV-infected individuals; and (4) marginally increased CTL activity. The immunomodulatory properties of tucaresol were confirmed by PCR analyses; additional data showed that tucaresol costimulated CD3-dependent triggering of T cells and that this stimulation was independent of CD28 costimulation. The immunomodulatory effects of tucaresol on T cell functions are characterized by a bell-shaped dose response curve; the action of the compound is optimal in the 100 to 300 microM range. Analyses of mitogen-stimulated apoptosis demonstrated that the lack of effect of tucaresol at higher doses is not the result of increased cell death, suggesting a role of functional impairment. These data confirm that tucaresol can stimulate T helper cell function and enhance the production of type 1 cytokines, thus eliciting cell-mediated immunity, and warrant its potential utility in the therapy of HIV infection. 相似文献
40.
Colombo T Frapolli R Bombardelli E Morazzoni P Riva A D'Incalci M Zucchetti M 《Journal of chromatography. B, Biomedical sciences and applications》1999,736(1-2):135-141
An HPLC assay was developed to determine the paclitaxel analogue 13-(N-tert.-butoxycarbonyl-beta-isobutylisoserinyl)-14-hydroxyb accatin-1,14-carbonate (IDN5109) and its epimer in mouse plasma. The method involves solid-phase extraction on cyano cartridges (recovery >75%), HPLC separation on symmetry shield column, a mobile phase of NaH2PO4 (10 mM) pH 5.2, acetonitrile (47:53) and detection at 227 nm. Retention times of IDN5109, its epiform and internal standard were 15, 24 and 25.5 min, respectively. The assay was linear from 0.10 to 10 microg/ml (r2 = 0.999), with a C.V. <5% and accuracy in the range of 95-107%. LOQ was 50 ng/ml for both compounds. Using this method IDN5109 pharmacokinetic was determined in mice. 相似文献